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Abstract 
Review on t(6;10)(q22;q24), with data on the genes 
involved. 
Keywords 
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Clinics and pathology 
Disease 
Anaplastic large cell lymphoma, ALK negative 
Note 
Only one case to date (Crescenzo et al., 2015). No 
individual data, no clinical data. 
Prognosis 
No data 
Genes involved and 
proteins 
NFKB2 
Location 
10q24.32 
Protein 
The gene encodes a subunit of the transcription 
factor complex nuclear factor-kappa-B. NFKB2 is a 
rapidly acting primary transcription factor found in  
all cell types. It is involved in the cellular responses 
to stimuli such as cytokines and stress and plays a 
key role in regulating the immunological response to 
infections. 
ROS1 
Location 
6q22.1 
Protein 
This proto-oncogene belongs to the subfamily of 
tyrosine kinase insulin receptor genes and expresses 
in a variety of tumor cell lines.  
ROS1 is an integral membrane protein with tyrosine 
kinase activity, that may function as a growth or 
differentiation factor receptor. 
Result of the chromosomal 
anomaly 
Hybrid gene 
5' NFKB2 - 3' ROS1 
Description 
Nucleotide sequence analyses revealed that NFKB2 
(exon 1-13) is fused to the intracytoplasmic domain 
of ROS1 accompanied by loss of the NFKB2 ankyrin 
region, that is necessary for the translation of 
constitutively active NFKB-fusion proteins and its 
oncogenic role [Crescenzo et al., 2015]. 
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Fusion protein 
Oncogenesis 
NFKB2/ROS1 is a chimeric transcription factor with 
oncogenic potential that leads to the constitutive 
activation of STAT3 in the absence of either JAK-
STAT3 mutations.  
The ectopic expression of NFKB2/ROS1 is 
associated with the phosphorylation of JAK (JAK2 - 
JAK3) and STAT3. NFKB2/ROS1 fusion induces 
the expression of genes involved in membrane 
trafficking, replication, protein export, TNF 
signaling, T cell activation.  
This, in turn, may lead to a widespread derangement 
of several metabolic and signaling pathways, which 
ultimately concur to neoplastic transformation 
[Crescenzo et al., 2015, Tabbo et al, 2016]. 
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